Acadia Pharma ($ACAD) plunged yesterday after CNN said NUPLAZID was not safe. The drug was approved two years ago and treats Parkinson's psychosis. $ACAD, ACADIA Pharmaceuticals Inc. / H1 Acadia responded:"it would not be appropriate to compare the number of reports from ACADIA's regular interactions with patients, caregivers and physicians gathered through spontaneous reports and through our specialty distribution channels to spontaneous reporting occurring with other anti psychotics."Related speculations: Synergy Pharma $SGYP will have trouble recovering. Too much headwinds in opex for launching its trulance drug.$ACAD stock will rebound.Agree or disagree?Login now to vote. Join the group of Value Stocks. With Over 800 members. Comment below.